GlassScriptPhysician profile
Robert N Schnitzler
NPI 1386743839
$2,397.25
in general payments reported to CMS, 2019-2025
24 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $319 · 2021: $166 · 2022: $394 · 2023: $159 · 2024: $424 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $381.82 | 2019-2025 | |
| Boston Scientific Corporation | $288.83 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $260.14 | 2022-2025 | Onpattro, Amvuttra |
| Pfizer INC. | $217.06 | 2020-2022 | |
| Heartflow, INC. | $153.68 | 2025 | |
| Abbott Laboratories | $146.13 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2020 | |
| Amgen INC. | $123.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $98.76 | 2019-2024 | |
| Regeneron Pharmaceuticals, INC. | $89.32 | 2019 | |
| Abiomed | $89.10 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $73.82 | 2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $60.55 | 2019 | |
| Merck Sharp & Dohme LLC | $50.13 | 2021-2022 | |
| Biotronik INC. | $43.27 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40.00 | 2019 | |
| Esperion Therapeutics, INC. | $30.82 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $25.53 | 2023 | Evkeeza, Praluent |
| Medicomp INC | $25.06 | 2023 | Telepatch Cardiac Monitor |
| Impulse Dynamics (USA) INC. | $23.48 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $20.01 | 2024 | Arcalyst |
| Novo Nordisk INC | $16.46 | 2024 | Rybelsus, Ozempic |
| United Therapeutics Corporation | $14.73 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schnitzler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.